虚弱和心力衰竭的双重负担
Cristiana Vitale1, Ilaria Spoletini2, Giuseppe M C Rosano3,4
1Clinical Academic Group, St. George's University Hospital, London, United Kingdom.
International journal of heart failure
|July 31, 2024
概括
在心力衰竭 (HF) 患者中,虚弱是常见的,增加死亡风险. 运动和营养等管理策略可以改善结果,但需要HF特定的评估工具.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 内部医学 内部医学
背景情况:
- 在心力衰竭 (HF) 患者中,脆弱性非常普遍,影响预后.
- 与强壮个体相比,仅仅预先脆弱就会使死亡风险增加一倍.
- 在HF中脆弱的最佳定义,评估和管理仍然未被定义.
研究的目的:
- 审查心力衰竭中脆弱的患病率,影响和管理.
- 突出需要HF特定的脆弱性评估工具和干预措施的需要.
主要方法:
- 关于心力衰竭中的脆弱性的文献评论.
- 分析现有的脆弱选工具及其在HF方面的局限性.
- 讨论潜在的管理策略,包括运动,营养和多学科护理.
主要成果:
- 虚弱影响高达80%的HF患者,通过炎症,神经激素变化,肉症和营养缺乏症恶化预后.
- 简单的选工具 (步行速度,握力) 可以预测结果,但缺乏高频特异性.
- 综合老年医学评估是理想的,但往往是不切实际的.
结论:
- 脆弱性显著加剧心力衰竭,需要进行常规查.
- 针对身体,认知和心理健康的干预措施至关重要.
- 对高频特异性脆弱性评估和管理进行进一步的研究是有必要的,以解决这种双重负担.
相关概念视频
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Heart Failure Drugs: Diuretics
355
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413


